Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB718
- Development stage
- Preclinical
- Lead developer
- PegBio
- Administration
- Subcutaneous
01
Overview
PB718 is a biologic therapeutic developed by PEG Biosciences for the treatment of drug addiction, specifically opioid addiction, and the management of pain. It is designed to target opioid receptors in the brain to reduce and prevent the effects of opiates, mitigate withdrawal symptoms, and minimize patient discomfort during the detoxification process. As a next-generation therapeutic, PB718 aims to provide a dual-purpose solution for both chronic pain and substance use disorders by modulating opioid receptor activity to prevent relapse.
02
Targets
Beyond the preview
Go deeper on PB718.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB718.